This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Boehringer gets most US antitrust claims over drug-device combination treatments dismissed

( March 27, 2025, 13:56 GMT | Official Statement) -- MLex Summary: Boehringer Ingelheim Pharmaceuticals was granted the dismissal of US claims accusing it of engaging in sham patent litigation to thwart generic competition in multiple markets, including those for Combivent Respimat and its generic equivalents, and Spiriva Respimat and its generic equivalents. US District Judge Denise J. Casper said that plaintiffs failed to show that Boehringer’s litigation was objectively baseless. Casper did maintain the claims for injunctive relief under the Clayton Act.See attached file. ...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Documents

Related Sections